New antibody drug for blood cancers tested in first human trial
NCT ID NCT05263739
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This was a very early (phase 1) study testing a new antibody drug called ESG206 in people with advanced B-cell blood cancers that had stopped responding to other treatments. The main goal was to check safety and find the right dose. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ESG206 (an antibody drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for certain blood cancers that have not responded to standard therapies.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data exists. Even if it had started, phase 1 trials are very early and most drugs do not prove effective or safe enough to move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Willing and able to provide written informed consent for the trial. * Male or female and at least 18 years of age. * Subjects must have a histologically confirmed (or documented), incurable B-cell hematologic malignancy that had progressed despite standard of care therapy and for which there was no alternative therapy of proven benefit or no effective standard therapy is available or tolerable. * Measurable or evaluable Disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Subject must have adequate organ function. Exclusion Criteria: * Has had prior chemotherapy, targeted therapy, immunotherapy or any other agents used as systemic treatment for cancer, within 14 days before first dosing. * Had major surgery within 4 weeks before first dosing. * Had undergone an autologous stem cell transplant within 100 days before first dosing. * Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, or renal disease). * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product or excipients. * Pregnant or breastfeeding women. * Unwillingness or inability to follow the procedures outlined in the protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-cell lymphoid malignancies are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.